FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2940832893> ?p ?o ?g. }

• W2940832893 abstract "Background Melphalan-based regimens, combined with Prednisone and Thalidomide (THAL)(MPT) or Bortezomib (V)(MPV), have been approved as standard therapy of non-transplant eligible newly diagnosed multiple myeloma (NDMM) patients. Similar to MPT and MPV also MP-Lenalidomide followed by Lenalidomide (LEN) maintenance (MPR-R) has a superior PFS compared to MP. We compared MPT followed by THAL maintenance (MPT-T) versus MPR-R in non-transplant eligible NDMM patients. Study design Patients were randomised to receive nine 4-weekly cycles of MPT (MEL 0.18 mg/kg days 1-4, PRED 2 mg/kg days 1-4 plus THAL 200 mg days1-28) followed by THAL maintenance 100 mg d1-28 until progression or nine cycles of MPR (MEL 0.18 mg/kg days 1-4, PRED 2 mg/kg days 1-4 plus LEN 10 mg days 1-21) followed by LEN maintenance 10 mg d1-21 until progression. In order to detect an improvement of progression free survival (PFS) with 90% power and a HR of 0.714 for patients receiving MPR-R, 668 patients had to be randomized. The study started in January 2009 and was closed for inclusion in October, 2012. This analysis is restricted to the first 560 eligible randomized patients, i.e. 280 per arm, including the minimum number of events (377) that were required for the primary endpoint. Results Patient characteristics are presented in table 1. The median follow up is 32.6 months. The results of FISH analysis on isolated plasma cells, being performed in 75% and 79% of patients treated with MPT-T and MPR-R respectively, are shown in table 1. Complete response (CR) rates on protocol were 10% (MPT-T) vs. 13% (MPR-R), (p=0.43), ≥ very good partial response (VGPR) rates were 49% vs. 44% (p=0.31), and ≥ partial response (PR) rates were 82% vs. 83% (p=0.91). The median PFS was 20 months (95% CI; 18-23) for MPT-T vs. 22 months (95% CI; 19-27) for MPR-R (HR = 0.86, 95% CI = 0.70-1.05, p-value adjusted for ISS =0.14). The median overall survival (OS) was 49 months (95% CI; 43-54) for MPT-T vs. 50 months (95% CI; 45-54) for MPR-R (HR = 0.79, 95% CI = 0.60-1.05, p-value adjusted for ISS =0.11). Del(17p) was associated with a lower PR rate (OR=0.45, 95% CI 0.22-0.95, p=0.003), worse PFS (HR=1.74, 95% CI 1.20-2.54, p=0.007) and decreased OS (HR=1.98, 95% CI 1.19-3.28, p=0.01). Grade ≥ 3 toxicity during induction and maintenance is presented in table 2. The dose intensity of THAL during induction was median 53% (mean 56%, SD 34%), vs. median 88% (mean 73%, SD 32%) for LEN during induction. There was a significantly higher discontinuation rate due to toxicity associated with THAL (28% within one year, and 58% within two years) vs LEN maintenance (10% within one year, and 16% within two years)(p" @default.
• W2940832893 created "2019-05-03" @default.
• W2940832893 creator A5012101669 @default.
• W2940832893 creator A5075158810 @default.
• W2940832893 creator A5083385949 @default.
• W2940832893 date "2014-01-01" @default.
• W2940832893 modified "2023-09-23" @default.
• W2940832893 title "Randomized Phase III Trial in Non-Transplant Eligible Patients with Newly Diagnosed Symptomatic Multiple Myeloma Comparing Melphalan-Prednisone-Thalidomide Followed By Thalidomide Maintenance (MPT-T) Versus Melphalan-Prednisone-Lenalidomide Followed By Ma" @default.
• W2940832893 hasPublicationYear "2014" @default.
• W2940832893 type Work @default.
• W2940832893 sameAs 2940832893 @default.
• W2940832893 citedByCount "0" @default.
• W2940832893 crossrefType "journal-article" @default.
• W2940832893 hasAuthorship W2940832893A5012101669 @default.
• W2940832893 hasAuthorship W2940832893A5075158810 @default.
• W2940832893 hasAuthorship W2940832893A5083385949 @default.
• W2940832893 hasConcept C126322002 @default.
• W2940832893 hasConcept C141071460 @default.
• W2940832893 hasConcept C2776063141 @default.
• W2940832893 hasConcept C2776364478 @default.
• W2940832893 hasConcept C2776694085 @default.
• W2940832893 hasConcept C2778283404 @default.
• W2940832893 hasConcept C2778684742 @default.
• W2940832893 hasConcept C2778720950 @default.
• W2940832893 hasConcept C2779609412 @default.
• W2940832893 hasConcept C71924100 @default.
• W2940832893 hasConcept C90924648 @default.
• W2940832893 hasConceptScore W2940832893C126322002 @default.
• W2940832893 hasConceptScore W2940832893C141071460 @default.
• W2940832893 hasConceptScore W2940832893C2776063141 @default.
• W2940832893 hasConceptScore W2940832893C2776364478 @default.
• W2940832893 hasConceptScore W2940832893C2776694085 @default.
• W2940832893 hasConceptScore W2940832893C2778283404 @default.
• W2940832893 hasConceptScore W2940832893C2778684742 @default.
• W2940832893 hasConceptScore W2940832893C2778720950 @default.
• W2940832893 hasConceptScore W2940832893C2779609412 @default.
• W2940832893 hasConceptScore W2940832893C71924100 @default.
• W2940832893 hasConceptScore W2940832893C90924648 @default.
• W2940832893 hasOpenAccess W2940832893 @default.
• W2940832893 hasRelatedWork W2106530862 @default.
• W2940832893 hasRelatedWork W2142368474 @default.
• W2940832893 hasRelatedWork W2212533564 @default.
• W2940832893 hasRelatedWork W2290822453 @default.
• W2940832893 hasRelatedWork W2298765957 @default.
• W2940832893 hasRelatedWork W2520502719 @default.
• W2940832893 hasRelatedWork W2552255104 @default.
• W2940832893 hasRelatedWork W2555687110 @default.
• W2940832893 hasRelatedWork W2558999476 @default.
• W2940832893 hasRelatedWork W2562900140 @default.
• W2940832893 hasRelatedWork W2570291372 @default.
• W2940832893 hasRelatedWork W2581502552 @default.
• W2940832893 hasRelatedWork W2586712442 @default.
• W2940832893 hasRelatedWork W2588960832 @default.
• W2940832893 hasRelatedWork W2591064797 @default.
• W2940832893 hasRelatedWork W2606891899 @default.
• W2940832893 hasRelatedWork W2978193291 @default.
• W2940832893 hasRelatedWork W2979878259 @default.
• W2940832893 hasRelatedWork W3092332842 @default.
• W2940832893 hasRelatedWork W3095175361 @default.
• W2940832893 isParatext "false" @default.
• W2940832893 isRetracted "false" @default.
• W2940832893 magId "2940832893" @default.
• W2940832893 workType "article" @default.